G&S Capital LLC acquired a new position in ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 30,300 shares of the biotechnology company’s stock, valued at approximately $125,000.
Other hedge funds have also bought and sold shares of the company. BlackRock Inc. increased its position in ZIOPHARM Oncology by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock valued at $35,187,000 after buying an additional 280,003 shares in the last quarter. Deutsche Bank AG increased its position in ZIOPHARM Oncology by 141.1% in the 4th quarter. Deutsche Bank AG now owns 294,287 shares of the biotechnology company’s stock valued at $1,216,000 after buying an additional 172,227 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in ZIOPHARM Oncology in the 3rd quarter valued at about $746,000. Virtu Financial LLC increased its position in ZIOPHARM Oncology by 877.6% in the 4th quarter. Virtu Financial LLC now owns 98,638 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 88,548 shares in the last quarter. Finally, Virtus Fund Advisers LLC bought a new stake in ZIOPHARM Oncology in the 4th quarter valued at about $338,000. 40.19% of the stock is owned by hedge funds and other institutional investors.
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) opened at $4.44 on Wednesday. ZIOPHARM Oncology Inc. has a twelve month low of $3.33 and a twelve month high of $7.88.
A number of analysts recently commented on the company. Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the stock a “buy” rating in a report on Monday, March 5th. ValuEngine lowered ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. BidaskClub lowered ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $7.50.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3261224/gs-capital-llc-invests-125000-in-ziopharm-oncology-inc-ziop.html.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP).
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.